J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...

J&J’s Innovative Medicine unit is showing a growing trend. The segment’s sales rose 5.8% in 2024 on an organic basis. In 2025, J&J expects growth in the Innovative Medicine segment despite the ...

J&J innovative medicine, solid tumours and clinical development vice-president Kiran Patel stated: “We are redefining care for patients with non-small cell lung cancer by advancing innovative ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them," noted Bill Martin, J&J Innovative Medicine's ...

Kevin Hamill, President, U.S. Immunology, Johnson & Johnson Innovative Medicine ... “As a company, J&J is committed to leading where medicine is going,” Hamill says.

It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism ...

The PhRMA Foundation announced the appointment to its Board of Directors of Dr. John C. Reed, MD, PhD, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson (J&J), and Dr. Donatello ...